Shaily Engineering reported strong FY26 results with consolidated PAT up 83% YoY to ₹169.9 crore and revenue up 26% to ₹990.7 crore.
The company received a major ₹423 crore order for pen injectors and secured EMA approval for Teriparatide, driving healthcare segment growth.
An enabling resolution was approved to raise up to ₹500 crore to fund expansion into consumer electronics and semiconductor supply chains.
Operational highlights include the commercial launch of Semaglutide pens, new contracts in the GLP-1 segment, and onboarding of 7+ new customers.